Skip to main content

Table 2 Pathologic response following neoadjuvant therapy

From: Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer

 

Neoadjuvant chemotherapy

Neoadjuvant SBRT (dose / fractions)

Pathologic response (Evans’ criteria)

01

Gem./Cape.

36 Gy / 3

IV

02

Gem./Cape.

36 Gy / 3

IV

03

FOLFIRINOX, Gem./Abraxane

36 Gy / 3

IV

04

Gem./Erlotinib

24 Gy / 1

III

05

Gem./Cape.

24 Gy / 1

III

06

Gem.

24 Gy / 1

IIb

07

FOLFIRINOX

36 Gy / 3

IIb

08

N/A

36 Gy / 3

IIa

09

Gem./Cape.

36 Gy / 3

IIa

10

Gem./Cape.

24 Gy / 1

IIa

11

Gem./Cape.

24 Gy / 1

IIa

12

Gem./Cape.

30 Gy /3

IIa

  1. 25% of patients achieved a complete pathologic (pCR) response to neoadjuvant therapy (Evans’ grade: IV), and an additional 16.7% of patients had >90% tumor cell destruction (Evans’ grade: III). In total, 58.3% of patients had at least 50% of tumor cell destruction (Evans’ Grade: IIb – IV). For those achieving pCR, SBRT dose was 36 Gy in 3 fractions and neoadjuvant chemotherapy was gemcitabine-based. [Abbreviations: Gem Gemcitabine, Cape Capecitabine].